{"altmetric_id":4691359,"selected_quotes":["C Saura $RHHBY Lorelei trial of taselisib #ESMO17 Endpoints vs CT entry"],"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Genentech, Inc."],"first_seen_on":"2015-10-28T14:13:27+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1505346360,"links":["http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02273973?no_unk=Y&rcv_d=14&recr=Open&term=%22breast+cancer%22","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02273973","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02273973?term=Lorelei&rank=1","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02273973?term=LORELEI+trial&rank=1"],"nct_id":"NCT02273973","pubdate":"2014-10-22T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"A Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)","type":"clinical_trial_study_record"},"altmetric_score":{"score":26.5,"score_history":{"1y":17,"6m":17,"3m":17,"1m":17,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":26.5},"context_for_score":{"all":{"total_number_of_other_articles":8409376,"mean":7.0790526953473,"rank":341776,"this_scored_higher_than_pct":95,"this_scored_higher_than":8067169,"rank_type":"exact","sample_size":8409376,"percentile":95},"similar_age_3m":{"total_number_of_other_articles":245792,"mean":9.7961712430479,"rank":15847,"this_scored_higher_than_pct":93,"this_scored_higher_than":229920,"rank_type":"exact","sample_size":245792,"percentile":93},"this_journal":{"total_number_of_other_articles":24768,"mean":10.533010538216,"rank":1129,"this_scored_higher_than_pct":95,"this_scored_higher_than":23632,"rank_type":"exact","sample_size":24768,"percentile":95},"similar_age_this_journal_3m":{"total_number_of_other_articles":1129,"mean":14.829914893617,"rank":79,"this_scored_higher_than_pct":93,"this_scored_higher_than":1050,"rank_type":"exact","sample_size":1129,"percentile":93}}},"demographics":{"poster_types":{"member_of_the_public":3,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":3,"Science communicators (journalists, bloggers, editors)":1}}},"geo":{"twitter":{"US":1,"FR":1,"AU":1}}},"counts":{"total":{"posts_count":7},"news":{"unique_users_count":2,"unique_users":["medpage_today","the_asco_post"],"posts_count":2},"blogs":{"unique_users_count":1,"unique_users":[369],"posts_count":1},"twitter":{"unique_users_count":4,"unique_users":["Breast_Trials","JacobPlieth","BiotechRadar","YoungChris27040"],"posts_count":4}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/Breast_Trials\/status\/525650124127494144","license":"datasift","citation_ids":[4691359],"posted_on":"2014-10-24T14:08:50+00:00","author":{"name":"Breast Trials","image":"https:\/\/pbs.twimg.com\/profile_images\/1432677618\/breash-cancer_normal.gif","description":"The ultimate source for breast cancer news and clinical trials","id_on_source":"Breast_Trials","tweeter_id":"318606361","geo":{"lt":"42.3604823","ln":"-71.0595678","country":"US"},"followers":3633},"tweet_id":"525650124127494144"},{"url":"http:\/\/twitter.com\/JacobPlieth\/statuses\/906131561753530368","license":"gnip","citation_ids":[4691359],"posted_on":"2017-09-08T12:26:14+00:00","author":{"name":"Jacob Plieth","url":"http:\/\/www.epvantage.com\/default.aspx","image":"https:\/\/pbs.twimg.com\/profile_images\/453547761401462784\/a2Lp0d3m_normal.jpeg","description":"Journalist covering biopharma at EP Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.","id_on_source":"JacobPlieth","tweeter_id":"873399943","geo":{"lt":null,"ln":null},"followers":7690},"tweet_id":"906131561753530368"},{"url":"http:\/\/twitter.com\/BiotechRadar\/statuses\/906141244505694208","license":"gnip","rt":["JacobPlieth"],"citation_ids":[4691359],"posted_on":"2017-09-08T13:04:42+00:00","author":{"name":"Biotech Radar","image":"https:\/\/pbs.twimg.com\/profile_images\/693444152265146369\/T6cOJomc_normal.png","description":"Anticipate the catalysts of EU biotechs (focus on FR\/BE\/NL\/DE listed in Paris\/Bru.\/Ams.).Views=owner's only.RT\/like =\/= endorsement","id_on_source":"BiotechRadar","tweeter_id":"3142088601","geo":{"lt":46,"ln":2,"country":"FR"},"followers":2556},"tweet_id":"906141244505694208"},{"url":"http:\/\/twitter.com\/YoungChris27040\/statuses\/906154578986516481","license":"gnip","rt":["JacobPlieth"],"citation_ids":[4691359],"posted_on":"2017-09-08T13:57:41+00:00","author":{"name":"Chris Young","url":"https:\/\/m.facebook.com\/home.php?soft=bookmarks","image":"https:\/\/pbs.twimg.com\/profile_images\/832595198987296769\/VjFKip8q_normal.jpg","description":"Advocate #equality #disabilities #health LT #investor \ud83d\udd0eP-value mrkt intel\" #Biotech paradigm-shift research, pre-eminently humane. retweets not endorsements.","id_on_source":"YoungChris27040","tweeter_id":"1415149603","geo":{"lt":-37.83333,"ln":144.96667,"country":"AU"},"followers":1390},"tweet_id":"906154578986516481"}],"blogs":[{"title":"Peter Doshi: Roche to publicly post trial protocols\u2014just kidding","url":"http:\/\/blogs.bmj.com\/bmj\/2016\/01\/21\/peter-doshi-roche-to-publicly-post-trial-protocols-just-kidding\/","license":"public","citation_ids":[4691359,5022409,4520552,4520533,2397483,2147317,4554413,1619271],"posted_on":"2016-01-21T09:14:00+00:00","summary":"&ldquo;Thirdly, we will post the protocol of our trials as they are started and the results of trials once they are completed on two websites which are available to the public, clinicaltrials.gov and roche-trials.com.&rdquo;\nSo states Roche in describing o","author":{"name":"Latest BMJ blogs","url":"http:\/\/blogs.bmj.com\/bmj","description":"Just another blogs.bmj.com weblog"}}],"news":[{"title":"PI3K Inhibitor Ups Response in Early Breast Cancer","url":"http:\/\/ct.moreover.com\/?a=31783793789&p=1pl&v=1&x=QHeXH4bNE49UnCLN6O53EQ","license":"public","citation_ids":[4691359],"posted_on":"2017-09-09T17:29:11+00:00","summary":"Action Points Note that this study was published as an abstract and presented at a conference.","author":{"name":"MedPage Today","url":"http:\/\/www.medpagetoday.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/262\/normal\/Screen_Shot_2016-02-09_at_10.51.03.png?1455015082"}},{"title":"ESMO 2017: Adding Taselisib to Neoadjuvant Letrozole Improves Outcomes in Early Breast Cancer","url":"http:\/\/ct.moreover.com\/?a=31829035148&p=1pl&v=1&x=JdoO1X_RizO0uT8MwpXHgw","license":"public","citation_ids":[4691359],"posted_on":"2017-09-13T23:46:00+00:00","summary":"By The ASCO Post Posted: 9\/13\/2017 11:56:25 AM Last Updated: 9\/13\/2017 12:18:27 PM Tweet this page Advertisement The study showed that objective response rate was better in patients who received taselisib compared to placebo (50% vs 39.3%), but\u2026","author":{"name":"The ASCO Post","url":"http:\/\/www.ascopost.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/496\/normal\/Screen_Shot_2016-02-03_at_09.24.05.png?1454491455"}}]}}